We are experts in myeloma…
it’s all we do

 

Our singular focus on myeloma ensures that we bring unparalleled expertise and dedication to everything we do

 

From actionable insights to strategic engagement with leading KOLs and community clinicians, our full suite of  services empowers you to lead in the myeloma market

Everything you need to navigate the myeloma market

Insights

MYInsights provides real-time insights to data being presented at conferences or from the latest publications. Gain an understanding of how the experts view the data.

Data Compass conference reports. Collecting insights at medical conferences shouldn’t be hard. MYELOMA360 makes it easy!

Engagements

MYBoard is a new format for Advisory Boards.

In place of single company events, MYBoard is an independent full day advisory board fully managed by MYELOMA360, with four 2-hour time slots for multiple companies, allowing for a focused, efficient, dedicated session to generate insights around your strategic objectives.

Strategy & Consulting

We are a team of seasoned biopharmaceutical specialists dedicated to helping companies strategize and plan their marketing, clinical development and medical affairs activities.

Our expertise is focused in myeloma across the full development lifecycle, allowing us to provide tailored solutions to drive your company’s success.

Everything you need to navigate the myeloma market

Latest insights

Myeloma News

Single Infusion of Cilta-Cel Yields 5-Year Progression-Free Survival in Multiple Myeloma

Source: Pharmacy Times articles Cilta-cel shows promise as a CAR T-cell therapy, offering long-term remission for relapsed/refractory multiple myeloma patients without maintenance treatment. Read More

Sequencing Strategies and the Role of Combination Therapy

Source: Pharmacy Times articles Panelists discuss how evolving treatment pathways at Emory Healthcare, including earlier use of emerging therapies and off-label combination treatments, are shaping the management of chronic graft-vs-host disease (cGVHD), with an...

ASCO 2025: Fixed-Duration Treatment Emerges as Future of Multiple Myeloma Management

Source: Pharmacy Times articles Saad Usmani, MD, MBA, FACP, FASCO, explores treatment duration, patient characteristics, and toxicity profiles in transplant-ineligible patients with newly diagnosed multiple myeloma. Read More

ASCO 2025: Adding Carboplatin Did Not Result in Statistically Significant Improvements in Patients With TNBC

Source: Pharmacy Times articles New research finds that adding carboplatin to paclitaxel and adjuvant chemotherapy shows no significant survival benefits in triple-negative breast cancer (TNBC). Read More

Maximizing Your Pharmacy Fellowship Experience: Tips for Success

Source: Pharmacy Times articles Establishing a strong foundation and effective networking strategies and pursuing opportunities are key. Read More
Latest Data

Latest Publications

Hepatitis B and C virus infection and risk of multiple myeloma: a systematic review and meta-analysis

BMC Cancer. 2025 Jun 4;25(1):998. doi: 10.1186/s12885-025-14420-5. ABSTRACT BACKGROUND: Multiple...

Observation or treatment for smoldering multiple myeloma? A systematic review and meta-analysis of randomized controlled studies

Blood Cancer J. 2025 May 26;15(1):104. doi: 10.1038/s41408-025-01312-x. ABSTRACT While observation...

Email

info@myeloma360.com